Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 3INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Breast 1

Conditions

Breast Neoplasms 9Neoplasms 5Prostatic Neoplasms 3Solid Tumors 2Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Cancers 1Skin Diseases 1Prostatic Neoplasms, Castration-Resistant 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × ipatasertib × Clear all
NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting
176 enrolled
Gynecologic

Ovarian Neoplasms

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Hoffmann-La Roche

Phase 1 Completed
51 enrolled 20 charts
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡